Stada Arzneimittel (OTCMKTS: STDAF) recently received a number of ratings updates from brokerages and research firms:

  • 1/2/2018 – Stada Arzneimittel had its “sell” rating reaffirmed by analysts at Nord/LB.
  • 1/1/2018 – Stada Arzneimittel had its “sell” rating reaffirmed by analysts at DZ Bank AG.
  • 12/27/2017 – Stada Arzneimittel had its “sell” rating reaffirmed by analysts at Nord/LB.
  • 12/26/2017 – Stada Arzneimittel had its “sell” rating reaffirmed by analysts at DZ Bank AG.
  • 12/20/2017 – Stada Arzneimittel had its “sell” rating reaffirmed by analysts at DZ Bank AG.
  • 11/9/2017 – Stada Arzneimittel had its “sell” rating reaffirmed by analysts at DZ Bank AG.

Stada Arzneimittel (OTCMKTS STDAF) remained flat at $$100.50 during trading hours on Wednesday. The company had a trading volume of 1 shares, compared to its average volume of 28. Stada Arzneimittel has a 1 year low of $51.40 and a 1 year high of $100.50. The company has a market cap of $6,270.00, a P/E ratio of 61.28 and a beta of 1.41.

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications.

Receive News & Ratings for Stada Arzneimittel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stada Arzneimittel and related companies with MarketBeat.com's FREE daily email newsletter.